Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden

T Srivastava, VS Prabhu, HJ Li, RF Xu, N Zarabi, YC Zhong, JM Pellissier, RF Perini, Ronald de Wit, R Mamtani

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
15 Downloads (Pure)
Original languageEnglish
Pages (from-to)663-670
Number of pages8
JournalEuropean urology oncology
Volume3
Issue number5
DOIs
Publication statusPublished - 2020

Research programs

  • EMC OR-01

Cite this